Sara Zaknoen - 01 May 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: Director
Signature: /s/ Nancy E. Denyes, as Attorney-in-Fact
Issuer symbol: ATYR
Transactions as of: 01 May 2025
Net transactions value: $0
Form type: 4
Filing time: 02 May 2025, 17:25:06 UTC
Previous filing: 23 May 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Zaknoen Sara	Director	C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO	/s/ Nancy E. Denyes, as Attorney-in-Fact	02 May 2025	0001602225

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATYR	Stock Option (right to buy)	Award	$0	+50,000		$0.000000	50,000	01 May 2025	Common Stock	50,000	$3.34	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.